anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This open-label treatment will examine improvement of speech output, verbal fluency, and other cognitive deficits associated with primary progressive aphasia (PPA) and progressive apraxia of speech (PAOS), by utilizing 1 milliamp transcranial direct current stimulation (tDCS) active treatment applied to left inferior frontal gyrus for 20 minutes over 10 sessions. There will be baseline testing, and follow up testing immediately after and 8 weeks after completion of treatment.
### Hypertension

Single doses of 20 mg of quinapril hydrochloride provide over 80% inhibition ofplasma ACE for 24 hours. Inhibition of the pressor response to angiotensin I is shorter-lived, with a20 mg dose giving 75% inhibition for about 4 hours, 50% inhibition for about 8 hours, and 20%inhibition at 24 hours. With chronic dosing, however, there is substantial inhibition of angiotensin IIlevels at 24 hours by doses of 20 to 80 mg.

Administration of 10 to 80 mg of quinapril hydrochloride to patients with mild to severe hypertensionresults in a reduction of sitting and standing blood pressure to about the same extent with minimaleffect on heart rate. Symptomatic postural hypotension is infrequent although it can occur in patientswho are salt-and/or volume-depleted (see WARNINGS). Antihypertensive activity commences within1 hour with peak effects usually achieved by 2 to 4 hours after dosing. During chronic therapy, mostof the blood pressure lowering effect of a given dose is obtained in 1 to 2 weeks. In multiple-dosestudies, 10 to 80 mg per day in single or divided doses lowered systolic and diastolic blood pressurethroughout the dosing interval, with a trough effect of about 5 to 11/3 to 7 mm Hg. The trough effectrepresents about 50% of the peak effect. While the dose-response relationship is relatively flat,doses of 40 to 80 mg were somewhat more effective at trough than 10 to 20 mg, and twice dailydosing tended to give a somewhat lower trough blood pressure than once daily dosing with the sametotal dose. The antihypertensive effect of quinapril hydrochloride continues during long-term therapy,with no evidence of loss of effectiveness.

Hemodynamic assessments in patients with hypertension indicate that blood pressure reductionproduced by quinapril is accompanied by a reduction in total peripheral resistance and renalvascular resistance with little or no change in heart rate, cardiac index, renal blood flow, glomerularfiltration rate, or filtration fraction.

Use of quinapril hydrochloride with a thiazide diuretic gives a blood pressure lowering effect greaterthan that seen with either agent alone.

In patients with hypertension, quinapril hydrochloride 10 to 40 mg was similar in effectiveness tocaptopril, enalapril, propranolol, and thiazide diuretics.

Therapeutic effects appear to be the same for elderly (≥65 years of age) and younger adult patientsgiven the same daily dosages, with no increase in adverse events in elderly patients.
Postoperative pain associated with total knee arthroplasty (TKA) can pose significant challenges in the recovery process of the patients undergoing this procedure. Traditionally, opioids have played a significant role in treating postoperative pain. It is well established that opioids are highly effective in relieving pain at rest, but are less effective in relieving pain associated with motion (e.g. ambulation, passive motion, and physical rehabilitation). Furthermore, the use of opioids for analgesia is associated with well-known side effects (such as: nausea, vomiting, constipation, ileus, bladder dysfunction, respiratory depression, pruritus, drowsiness, sedation, and allergic reaction). These opioid side effects, which range in severity, can significantly interfere with the rehabilitation process and contribute to a delay in hospital discharge.

Significant interest exists in the application of regional anesthetic techniques as an adjuvant to traditional opioid analgesics for pain control in patients after TKA. Specifically, the incorporation of femoral nerve blocks (FNB) as an adjunct in postoperative pain control has been widely reported in the anesthesia literature. While it has shown to be effective in post-operative pain control, it has introduced additional challenges for physical therapy and raised new concerns regarding the associated quadriceps muscle weakness. Until adequate quadriceps function returns, the need for knee immobilization devices to protect patients with traditional FNB from falls interferes with the early recovery process and the achievement of physical therapy milestones.
Disclosed are a pyrrole amide compound as represented in formula I, or pharmaceutically acceptable salts, polymorphs, hydrates, or solvate compounds. R 1  is chosen from hydrogen, hydroxyl, the cyano group, halogen, carboxyl, etc. R 2  and R 3  are chosen from hydrogen, hydroxyl, the cyano group, halogen, carboxyl, and alkyl of C 1  to C 6 , etc., R 2  and R 3  being same or different. R 4  are chosen from hydroxyl, the sulfhydryl group, amino-substituted phenyl, or the epoxy ketone group. The new compound as represented in formula I of the present invention expresses good deacetylase inhibitory activity and has the potential for preventing and/or treating diseases caused by histone deacetylase activity abnormality. Additionally, the new compound of the present invention has good inhibitory activity against different liver cancer cells, and has good prospect for clinical application.
Transparent protective device for the eye is provided in the form of a contact lens with a h older for th progressive distribution of a medicament or drug which is intended to be absorbed by the eye fluid. The lens, preferably of the corneal type, is made of a soft, transparent plastic material, such as P.V.C. It includes an applicator in the form of an annular cavity on the inside of the body of the lens and extending around the latter. It forms a kind of channel with an outlet along its summit and holds the medicament. The latter may be a liquid, a paste or a powder. Protuberances are provided below the channel to allow the eye fluid to collect and mix progressively with the medicament so that it can circulate freely behind the lens. Increased efficiency is obtained in obtaining the desired therapeutic and analgesic effects. The lens is cheap and can be thrown away after a short period of use.
Nalbuphine Hydrochloride Injection contains nalbuphine. As an opioid, nalbuphine exposes users to the risks of addiction, abuse, and misuse [see DRUG ABUSE AND DEPENDENCE].

Opioids are sought for non-medical use and are subject to diversion from legitimate prescribed use. Consider these risks when handling Nalbuphine Hydrochloride Injection. Strategies to reduce these risks include proper product storage and control practices for a C-II drug. Contact local state professional licensing board or state-controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
This two-armed randomized controlled trial (300 patients/arm) will compare Colorectal Web (CW), the interactive DA, to a non-interactive control website in ten practices in Metro Detroit. Patients will be adults aged 50 years and over, not current on CRCS. In the clinic before the patient-physician encounter, participants will complete a Patient Baseline Survey. They will be randomized to CW or the control website. Data will be collected after the patient reviews the respective website (Post-Intervention Survey), during the patient-physician encounter (digital audio recording), and after it (Post-Encounter Survey). Chart audit will be performed six months after the encounter to determine whether the patient underwent CRCS.
Curcuma xanthorrhiza Roxb., known locally as temulawak in Indonesia or koneng gede in Sundanese, is a member of the Zingiberaceae family and is native to Indonesia. Previous research related to Curcuma xanthorriza Roxb. and its impact on melanin synthesis was conducted using mushroom tyrosinase by Batubara et al. The study found that methanol extract of Curcuma xanthorriza Roxb. could decrease tyrosinase enzyme activity with an inhibition concentration 50% (IC50) of 0.27 mg/mL.

Research conducted by Lee et al. on curcumin from another Curcuma species, C. longa or turmeric, demonstrated that curcumin reduced melanin quantity, tyrosinase enzyme activity, and micropthalmia-associated transcription factor (MITF) protein. In an in-silico study, Mustarichie et al. reported that the three active compounds in Curcuma xanthorriza Roxb. could inhibit both tyrosinase enzyme and α-melanin stimulating hormone (α-MSH). Xanthorrizol exhibited the most effective interaction with the tyrosinase enzyme, while demethoxycurcumin showed the most effective interaction with α-MSH.

Up to this point, there has been no research on the effectiveness of 10% Curcuma xanthorriza Roxb. cream in treating melasma. Therefore, the researchers are motivated to investigate the efficacy of 10% Curcuma xanthorriza Roxb. cream as a depigmentation agent, based on the assessment of MASI scores and skin brightness levels in patients with epidermal-type melasma using split-face therapy.
The invention relates to application of Xiaoyao pills to a medicine for treating oral ulcer and novel application of Xiaoyao pills. Main ingredients of Xiaoyao pills are bupleurum, Chinese angelica, white paeony root, largehead atractylodes rhizome (stir-frying with bran), tuckahoe, liquorice (roasted), tree peony bark, cape jasmine fruit (roasted by ginger), mint and the like, and an excipient is honey. Xiaoyao pills have the functions of soothing lever, tonifying spleen, and nourishing blood for regulating menstruation, and are used for depression of hepatic qi, swelling pain in chest and hypochondrium, dizziness, anorexia and irregular menstruation. Through the comparison of the therapeutic effect and the recurrence rate of 45 patients (an observation group) who are treated by using lysozyme buccal tablets, vitamin B2 and Xiaoyao pills and suffer from recurrent oral ulceration, and 41 cases (a control group) who are treated only by using lysozyme buccal tablets and vitamin B2, the effective rate of the observation group is 93.3 percent and is higher than 75.6 percent of the control group, and the observation group has a remarkably strong therapeutic effect and has the significance (P(0.05). After the follow-up visit for one year, the recurrence rate of the observation group is 9 percent (4/45), and is remarkably lower than 22 percent (9/41) of the control group. Therefore, Xiaoyao pills are effective to the treatment of recurrent oral ulceration and are worthy to be promoted, and the recurrence rate is low.
Hypertrophic scar (HS) is a fibroproliferative skin disease characterized by abnormal wound healing and pathological excessive fibrosis of the skin. Currently, the molecular mechanism of the disease is still largely unknown, and there is no effective drug treatment. In this study, we explored the effect of Rynchopeterine on the formation of HS. HS fibroblasts (HSFs) were isolated from the HS tissues of patients recovering from severe burns. After treating HSFs with different concentrations of Rynchopeterine, CCK-8, EdU, and Annexin V-FITC/PI assays were used to detect the proliferation, apoptosis, and contractile ability of HSFs. RT-qPCR and Western blotting were performed to evaluate the effect of Rynchopeterine on the expression of miR-21 and hypoxia-inducible factor 1-alpha subunit suppressor (HIF1AN). The dual-luciferase reporter gene was used to verify the targeting relationship between miR-21 and HIF1AN. Rynchopeterine reduced the expression of Col1a2, Col3a1, and α-SMA, inhibited proliferation and contraction of HSFs, and increased apoptosis in a dose-dependent manner. miR-21 was highly expressed in HS tissues and HSFs, and Rynchopeterine could inhibit miR-21 expression. Overexpression of miR-21 and knockdown of HIF1AN increased proliferation, activation, contraction, and collagen synthesis of HSFs, and inhibited their apoptosis. In vivo, Rynchopeterine could reduce the collagen content of the dermis and the positive ratio of PCNA and α-SMA. Rynchopeterine is a good therapeutic agent for HS, which up-regulates the expression of HIF1AN by inhibiting miR-21, thereby inhibiting the formation of HS.
Fatal and/or serious infections occurred in 48% of patients treated with Zydelig in combination with rituximab or with unapproved combination therapies [see Adverse Reactions (6.1)]. The most common infections were pneumonia, sepsis, and febrile neutropenia. Treat infections prior to initiation of Zydelig therapy. Monitor patients on Zydelig for signs and symptoms of infection, and interrupt Zydelig for Grade 3 or higher infection [see Dosage and Administration (2.2)].

Serious or fatal Pneumocystis jirovecii pneumonia (PJP) or cytomegalovirus (CMV) occurred in <1% of patients treated with Zydelig. Provide PJP prophylaxis during treatment with Zydelig. Interrupt Zydelig in patients with suspected PJP infection of any grade, and permanently discontinue Zydelig if PJP infection of any grade is confirmed. Regular clinical and laboratory monitoring for CMV infection is recommended in patients with history of CMV infection or positive CMV serology at the start of treatment with Zydelig. Interrupt Zydelig in the setting of positive CMV PCR or antigen test until the viremia has resolved. If Zydelig is subsequently resumed, patients should be monitored by PCR or antigen test for CMV reactivation at least monthly [see Dosage and Administration (2.2)].
Motivational interviewing (MI) has been demonstrated to be an effective intervention for alcohol use disorders (AUD). The consistency, magnitude, and durability of its effects suggest powerful mechanisms of behavior change (MOBC) operate to reduce drinking. A better understanding of the MOBC in MI is therefore important. Existing MOBC studies of MI have yielded limited and contradictory findings. The project proposes to conduct a small pilot study to disaggregate MI into its component parts and test full MI compared to MI without its directive strategies. This test will compare whether the directive elements of MI (Full MI, or FMI) are critical or whether MI effects may be attributable solely to its Rogerian, non-directive components (aka, Spirit-Only MI, or SOMI).

In addition, we will test whether hypothesized main effects of FMI are mediated via increases in commitment to reduce drinking early in treatment. Further, we will examine whether non-specific therapy factors alone (SOMI) significantly reduce drinking when compared to a Feedback Followed by Counseling (FFC) condition that controls for non-therapy factors and incorporates assessment and self-monitoring. We will also test whether SOMI's main effects are mediated by increases in mood and greater belief in the ability to change, as hypothesized by various theories.

Our work on MOBC for MI will take place in the context of studying brief, stand-alone treatments for individuals with primary AUD who seek to reduce, but not stop, drinking. We will recruit 90 individuals with AUD seeking treatment; collect daily process data during a pre-treatment week; and then assess and randomly assign them to 3 conditions: FMI, SOMI, and FFC. All participants will be followed for 9 weeks using daily Interactive Voice Recording (IVR) and in-laboratory assessments at weeks 0, 1, 4, and 8. Those in treatment conditions will receive 4 sessions of treatment at weeks 1, 2, 4, and 8. FFC will receive treatment after completing the week 8 assessment period. Participants in FMI and SOMI will be followed for an additional 4 weeks post-treatment (week 12).
Dengue viruses are the causative agents of dengue fever, dengue hemorrhagic fever, and dengue shock syndrome, which are mainly transmitted by Aedes aegypti and Aedes albopictus mosquitoes, and cost billions of dollars annually in patient treatment and mosquito control. Progress in understanding DENV pathogenesis and developing effective treatments has been hampered by the lack of a suitable small pathological animal model. Until now, the candidate vaccine, antibody, and drug for DENV have not been effectively evaluated. Here, we analyzed the pathogenicity of DENV-1 in type Ⅰ and type Ⅱ interferon receptor-deficient mice (AGB6) by intraperitoneal inoculation. Infected mice showed such neurological symptoms as opisthotonus, hunching, ataxia, and paralysis of one or both hind limbs. Viremia can be detected 3 days after infection. It was found that 6.98 × 103 PFU or higher dose induce 100% mortality. To determine the cause of lethality in mice, heart, liver, spleen, lung, kidney, intestinal, and brain tissues were collected from AGB6 mice (at an attack dose of 6.98 × 103 PFU) for RNA quantification, and it was found that the viral load in brain tissues peaked at moribund states (14 dpi) and that the viral loads in the other tissues and organs decreased over time. Significant histopathologic changes were observed in brain tissue (hippocampal region and cerebral cortex). Hematological analysis showed hemorrhage and hemoconcentration in infected mice. DENV-1 can be isolated from the brain tissue of infected mice. Subsequently, brain tissue transcriptome sequencing was performed to assess host response characteristics in infected AGB6 mice. Transcriptional patterns in brain tissue suggest that aberrant expression of pro-inflammatory cytokines induces antiviral responses and tissue damage. Screening of hub genes and their characterization by qPCR and ELISA, it was hypothesized that IL-6 and IFN-γ might be the key factors in dengue virus-induced inflammatory response. Therefore, this study provides an opportunity to decipher certain aspects of dengue pathogenesis further and provides a new platform for drug, antibody, and vaccine testing.
PURPOSE:To provide a medical plaster having moderate adhesivity, keeping the adhesivity for a long period and removable without pain, by adding an active component to a base obtained by compounding an alkali metal polyacrylate, a polyhydric alcohol and water at specific ratios. CONSTITUTION:The objective plaster can be produced by adding an active component (e.g. anti-inflammatory analgesic agent, antihistaminic agent, carcinostatic agent, etc.) to a base composed of 3-10W/W% alkali metal polyacrylate, 40-80W/W% polyhydric alcohol and 2-50W/W% water. The average molecular weight of the alkali metal polyacrylate is preferably >=3,000,000, and the polyhydric alcohol is preferably glycerol. The plaster has sufficiently high adhesivity to the skin, is removable without pain, has sufficient water-retainability and keeps the adhesivity stably for a long period.
Chronic kidney disease (CKD) is characterized by sympathetic nervous system (SNS) overactivity that contributes to increased vascular stiffness and cardiovascular risk. Although it is well established that SNS activity and vascular stiffness are substantially elevated in CKD, whether sex differences in autonomic and vascular function exist in CKD remains unknown. We tested the hypothesis that compared with females, males with CKD have higher baseline sympathetic activity that is related to increased arterial stiffness. One hundred twenty-nine participants (96 males and 33 females) with CKD stages III and IV were recruited and enrolled. During two separate study visits, vascular stiffness was assessed by measuring carotid-to-femoral pulse wave velocity (cfPWV), and resting muscle sympathetic nerve activity (MSNA) was measured by microneurography. Males with CKD had higher resting MSNA compared with females with CKD (68 ± 16 vs. 55 ± 14 bursts/100 heart beats, P = 0.005), whereas there was no difference in cfPWV between the groups (P = 0.248). Resting MSNA was not associated with cfPWV in both males and females. In conclusion, males with CKD have higher resting sympathetic activity compared with females with CKD. However, there was no difference in vascular stiffness between the sexes. There was no correlation between resting MSNA and cfPWV, suggesting that non-neural mechanisms may play a greater role in the progression of vascular stiffness in CKD, particularly in females.NEW & NOTEWORTHY Males with chronic kidney disease (CKD) have higher resting muscle sympathetic nerve activity (MSNA) compared with females. There was no correlation between MSNA and carotid-to-femoral pulse wave velocity (cfPWV), suggesting that non-neural mechanisms may play a greater role in the progression of vascular stiffness in CKD. Sex differences in SNS activity may play a mechanistic role in observations from epidemiological studies suggesting greater cardiovascular risk in males compared with females with CKD.
PURPOSE:To prevent the exfoliation of a high melting point metal silicide film by a method wherein the titanium of 30% or less is contained in the target consisting of a high melting point metal silicide alloy, and the electrode wiring of a semiconductor integrated circuit device is formed by deposition by performing a sputtering method using said target. CONSTITUTION:A silicon oxide film 2 is formed on the surface of a substrate as a gate insulating film, and a polycrystalline silicon film 3 is grown thereon by performing a chemical vapor deposition (CVD) method. Besides, a tungsten silicide film 4 is coated thereon using a sputtering method. At this time, a tungsten silicide alloy is used as a target, and in this case, the material containing 10% of titanium is contained in said target. Then, a photoresist 5 is patterned in gate electrode form on the target by performing a photolithographic method, and an etching is performed on the high melting point metal silicide film 4 and the polycrystalline silicon film 3 using the photoresist 5 as a mask. As a result, the gate electrode 6 of the double structure of the polycrystalline silicon film 3 and the high melting point metal silicide film 4, namely, a silicide structure, can be formed.
The invention provides an ibuprofen-codeine phosphate compounding preparation. The ibuprofen-codeine phosphate compounding preparation is composed of ibuprofen sustained-release pellets and codeine phosphate quick-release pellets. The ibuprofen sustained-release pellets comprise medicine-containing blank pellets and a sustained-release material coating the surfaces of the medicine-containing blank pellets. The medicine-containing blank pellets comprise the following ingredients, by weight, 55-75 parts of ibuprofen, 15-35 parts of disintegrating agent, 1-15 parts of filler and 1-5 parts of adhesive. The disintegrating agent is microcrystalline cellulose. The sustained-release material is polymethacrylate or ethyl cellulose. The codeine phosphate quick-release pellets comprise the following ingredients, by weight, 1-5 parts of codeine phosphate, 10-30 parts of disintegrating agent, 10-30 parts of filler and 1-5 parts of adhesive. When the ibuprofen-codeine phosphate compounding preparation is compared with the prior art, mutual influences of ibuprofen and codeine phosphate in the ibuprofen-codeine phosphate compounding preparation are small, and the sustained-release effect of ibuprofen is good and stable.
Approaches for glaucoma detection are described. In an example, a region of interest (ROI) portion of an input eye image, wherein the input eye image corresponds to a subject eye under evaluation for detecting presence of glaucoma, is obtained. A detection model pipeline is thereafter used, wherein the detection model pipeline is trained based on training data comprising one of training characteristic information corresponding to plurality of input eye image characteristics, and images associated with glaucoma, and wherein the detection model pipeline. The detection model pipeline is used to extract a characteristic information from the ROI portion of the input eye image to determine vertical cup-to-disc ratio (vCDR). Thereafter, classification output denoting probability of presence of glaucoma in the subject eye is obtained. Based on the above parameters, presence of glaucoma within the subject eye is determined.